SuperworthBiomarin Pharmaceutical EPS BMRN
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $0.37
- Latest quarter, Q2 FY26
- $0.23
- −81% on a year earlier
- Fiscal year 2025
- $1.78
- −19% on the year before
Biomarin Pharmaceutical's earnings per share was $0.37 over the twelve months to Jun 30, 2026, down 89% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.23, down 81% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 17% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.78 | −19% |
| FY2024 | $2.19 | +149% |
| FY2023 | $0.88 | +19% |
| FY2022 | $0.74 | n/a |
| FY2021 | −$0.36 | −108% |
| FY2020 | $4.41 | n/a |
| FY2019 | −$0.15 | n/a |
| FY2018 | −$0.44 | n/a |
| FY2017 | −$0.66 | n/a |
| FY2016 | −$3.84 | n/a |
| FY2015 | −$1.11 | n/a |
| FY2014 | −$0.92 | n/a |
| FY2013 | −$1.28 | n/a |
| FY2012 | −$0.95 | n/a |
| FY2011 | −$0.48 | −131% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.23 | −81% | $0.37 | |
| Q1 FY26 | $0.54 | −43% | $1.37 | |
| Q4 FY25 | −$0.24 | −138% | $1.78 | |
| Q3 FY25 | −$0.16 | −129% | $2.65 | |
| Q2 FY25 | $1.23 | +124% | $3.36 | |
| Q1 FY25 | $0.95 | +107% | $2.68 | |
| Q4 FY24 | $0.63 | +473% | $2.19 | |
| Q3 FY24 | $0.55 | +162% | $1.67 | |
| Q2 FY24 | $0.55 | +90% | $1.33 | |
| Q1 FY24 | $0.46 | +70% | $1.07 | |
| Q4 FY23 | $0.11 | n/a | $0.88 | |
| Q3 FY23 | $0.21 | n/a | $0.77 |
Against its peers
Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $1.00 |
Where Biomarin Pharmaceutical ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Biomarin Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.